Here, we describe a pharmacogenetics approach which allows to selectively and reversibly inactivate LC neurons using Designer Receptors Completely Activated by Designer Prescription drugs (DREADD). We exhibit the expression on the hM4Di DREADD could be limited to noradrenergic LC neurons and that the level of LC inhibition is often adjusted https://rogerk493tmm2.qodsblog.com/profile